Medicare AdvantagePrior AuthMedium impact
Nulibry™ (fosdenopterin) (Revised)
Humana·Pediatrics, Neurology, Genetics·Medicare Advantage
Effective date
Nov 26, 2025
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage updated its prior authorization policy for Nulibry (fosdenopterin) on November 26, 2025. The policy clarifies coverage for molybdenum cofactor deficiency Type A treatment with two approval pathways: initial 3-month approvals for members with pending genetic testing based on presumed diagnosis, and plan-year duration approvals for members with confirmed MOCS1 gene mutations. This is a newly revised policy requiring billing teams to understand and implement the dual approval duration structure.
Action Required
By December 10, 2025: Billing and prior authorization teams must review and implement this revised Nulibry policy in Humana Medicare Advantage accounts. Specific actions: (1) Update prior authorization submission protocols to distinguish between pending genetic testing claims (3-month initial/renewal approvals) vs. confirmed genetic testing claims (plan-year duration approvals); (2) Ensure prior authorization requests include either documented biochemical testing results (elevated urinary sulfites or S-sulfocysteine) for presumed diagnosis OR genetic test confirmation of MOCS1 mutation; (3) Train billing staff on approval duration differences—claims submitted after 3-month authorization expires for pending-test patients will be denied if reauthorization not obtained; (4) Update internal tracking systems to flag Nulibry intravenous solution claims for mandatory prior authorization before submission; (5) Verify member status in Humana system to confirm this is a Medicare Advantage plan before applying this policy. Failure to obtain prior authorization or submit with incorrect approval duration will result in claim denial.